Transforming the treatment
of heart disease

Who we are

Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease. The company was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany.

Meet our team

Our team at Draupnir Bio is driven by a deep commitment to scientific excellence, and by the desire to bring innovative therapies to patients.

Management

Andrew Hotchkiss

Chief Executive Officer

Anna Quattropani

Chief Discovery Officer

Camilla Gustafsen

Co-Founder and VP Biology

Casper Tind Hansen

Chief Business Officer

Margrit Schwarz

Chief Operating Officer

Simon Glerup

Co-Founder and Chief Scientific Officer

Board

Eva-Lotta Allan

Chair of the Board

Emmanuelle Coutanceau

Partner at Novo Seeds

Rob Scott

Independent Director

Roel Bulthuis

Managing Partner at INKEF

Simon Glerup

Co-Founder and Chief Scientific Officer

Stefan Luzi

Partner at Gilde Healthcare

Scientific Advisory Board

Professor Anne Tybjærg Hansen

University of Copenhagen

Professor Jay D. Horton

University of Texas Southwestern Medical Center

Professor John Kastelein

University of Amsterdam

Professor Peter Seeberger

Max-Planck Institute for Colloids and Interfaces, Potsdam

Our stories

Get to the heart of what we’re doing here at Draupnir Bio to transform the treatment of heart disease.

Our history

Draupnir Bio is a spin out from Aarhus University and the Max-Planck Society based on the breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger.

2021

Draupnir Bio establishes Scientific Advisory Board.

September

Draupnir Bio establishes Scientific Advisory Board.

Draupnir Bio moves R&D site to INCUBA Skejby

August

Draupnir Bio expands research operations with new R&D facility at INCUBA research park.

Anna Quattropani joins Draupnir Bio as CDO.

July

Anna Quattropani joins Draupnir Bio as CDO.

June

Andrew Hotchkiss joins Draupnir Bio as CEO.

2020

March

Margrit Schwarz joins Draupnir Bio as COO.

2019

October

Draupnir Bio funded by a 30 M EUR series A investment by Novo Seeds, Gilde Healthcare Partners, INKEF Capital and High-Tech Gründerfonds.

2018

December

Seed-stage investment led by Novo Seeds and High-Tech Gründerfonds.

2017

April

Draupnir Bio founded with investment from founders and grant from the Novo Nordisk Foundation.

© Draupnir Bio